SCHEMBL656003

SCHEMBL656003

N#Cc1cc(N)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 4/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 1/20 0.48
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
PDE10A Q9Y233 1/20 0.46
MAPT P10636 5/20 0.46
HPGD P15428 3/20 0.46
CYP3A4 P08684 3/20 0.43
MEN1 O00255 2/20 0.43
CYP2C19 P33261 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
HSD17B10 Q99714 3/20 0.42
CASP1 P29466 2/20 0.42
ALOX15 P16050 2/20 0.42
TNF P01375 1/20 0.42
HSPD1 P10809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029743 0.82 KDM4E (0.52) KDM4EALDH1A1USP2LMNACA1
SCHEMBL30839883 0.78 KDM4E (0.69) KDM4EALDH1A1USP2LMNAMAPT
SCHEMBL204121 0.78 KDM4E (0.69) KDM4EALDH1A1USP2LMNAMAPT
SCHEMBL13646420 0.77 CA1 (0.46) KDM4EALDH1A1USP2CA1CA2
SCHEMBL615129 0.76 KDM4E (0.55) KDM4EALDH1A1USP2LMNAMAPT
SCHEMBL2638947 0.76 KDM4E (0.55) KDM4EALDH1A1USP2LMNAMAPT
SCHEMBL29802150 0.76 KDM4E (0.55) KDM4EALDH1A1USP2LMNAMAPT
SCHEMBL1267040 0.76 ESR2 (0.44) CA2XDHSNCAESR2
SCHEMBL17498338 0.75 HPGD (0.45) KDM4EALDH1A1USP2LMNACA1
SCHEMBL6572584 0.75 ESR2 (0.47) KDM4EALDH1A1USP2LMNACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119639092-A Chemical corrosion resistant rubber material and chemical corrosion resistant nitrile glove 江西中红普林医疗制品有限公司 2025-03-18 CN claimed
CN-119639092-A Chemical corrosion resistant rubber material and chemical corrosion resistant nitrile glove 江西中红普林医疗制品有限公司 2025-03-18 CN disclosed
WO-2024226603-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-10-31 WO disclosed
WO-2024008909-A1 INHIBITORS OF CORONAVIRUS JANSSEN PHARMACEUTICA NV (BE) 2024-01-11 WO disclosed
WO-2024008909-A1 INHIBITORS OF CORONAVIRUS JANSSEN PHARMACEUTICA NV (BE) 2024-01-11 WO disclosed
WO-2023031308-A1 CCR2 INHIBITORS ARTICA THERAPEUTICS B.V. (NL) 2023-03-09 WO disclosed
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses Rigel Pharmceuticals, Inc. (US) 2020-11-10 US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20200246347-A1 Substituted Pyrrolopyridine-Derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-08-06 US disclosed
EP-1558567-A1 NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-08-03 EP disclosed
US-20050038243-A1 Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents MIDCAP FINANCIAL TRUST 2005-02-17 US disclosed
EP-1471915-A2 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES Rigel Pharmaceuticals, Inc. (US) 2004-11-03 EP disclosed
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-05 US disclosed
WO-2004039764-A1 NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-05-13 WO disclosed
US-20040029902-A1 Antiinflamamtory agents MIDCAP FINANCIAL TRUST 2004-02-12 US disclosed
WO-2003063794-A2 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2003-08-07 WO disclosed
US-5382502-A Photography, simplified synthesis EASTMAN KODAK COMPANY (US) 1995-01-17 US disclosed
EP-0071535-B1 (4-(2 AND/OR 3-THIENYLACETAMIDO)-PHENOXY)-HYDROXYAMINOPROPANES, THEIR PREPARATION, THEIR THERAPEUTIC USE AND INTERMEDIATES CARPIBEM (CENTRE D'ACTIVITE ET DE RECHERCHE PHARMACEUTIQUE INDUSTRIELLE BIOLOGIQUE ET MEDICALE) Société Anonyme dite: (FR) 1987-01-14 EP disclosed
EP-0071535-A1 (4-(2 and/or 3-Thienylacetamido)-phenoxy)-hydroxyaminopropanes, their preparation, their therapeutic use and intermediates CARPIBEM (CENTRE D'ACTIVITE ET DE RECHERCHE PHARMACEUTIQUE INDUSTRIELLE BIOLOGIQUE ET MEDICALE) Société Anonyme dite: (FR) 1983-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029902-A1 Antiinflamamtory agents FCER2, FCGR1A, HNMT KDM4E 2664/4885ALDH1A1 2723/4885USP2 1650/4885
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds MCHR2, MCHR1, NPY1R KDM4E 1359/4885ALDH1A1 4267/4885USP2 2396/4885
US-20200246347-A1 Substituted Pyrrolopyridine-Derivatives MAP4K4, MAP3K4, MAP4K3 KDM4E 733/4885ALDH1A1 3945/4885USP2 4033/4885
US-20050038243-A1 Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents FCER2, FCGR1A, FCGR2A KDM4E 4318/4885ALDH1A1 2302/4885USP2 2091/4885
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A KDM4E 2840/4885ALDH1A1 2891/4885USP2 2540/4885
US-10828301-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A KDM4E 2840/4885ALDH1A1 2891/4885USP2 2540/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK KDM4E 1645/4885ALDH1A1 4184/4885USP2 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.